Key result
Phytochemicals offer preclinical cardioprotection against doxorubicin toxicity but face clinical bioavailability and safety limitations.
Why the study?
Doxorubicin causes dose-dependent cardiotoxicity, and concerns over dexrazoxane's long-term safety and potential interference with antitumor effectiveness have driven the search for safer cardioprotective alternatives.
Do phytochemicals and herbal compounds provide effective cardioprotection against doxorubicin-induced cardiotoxicity?
Do phytochemicals and herbal compounds provide effective cardioprotection against doxorubicin-induced cardiotoxicity?
While phytochemicals show preclinical promise for preventing doxorubicin-induced cardiotoxicity, innovative delivery systems are needed to overcome significant pharmacological barriers to clinical use.
Answers are grounded in this paper and cite their sources.
Does not yet support clinical use of phytochemicals against doxorubicin cardiotoxicity; leaves open optimized delivery in future trials.
Doxorubicin, an anthracycline antibiotic extensively used in cancer treatment, is limited by its dose-dependent cardiotoxicity caused by oxidative stress, mitochondrial dysfunction, inflammation, and cardiomyocyte apoptosis-ultimately leading to cardiomyopathy, heart failure, and decreased quality of life. Although dexrazoxane is the only FDA-approved cardioprotective agent, concerns about its long-term safety and potential interference with doxorubicin's antitumor effectiveness have increased the search for safer alternatives. This study investigates the cardioprotective effects of phytochemicals and herbal compounds that target key signalling pathways involved in doxorubicin-induced cardiotoxicity, specifically PI3K/Akt, AMPK/SIRT1, Nrf2/Keap1, NF-κB, and Akt/mTOR/GSK-3β. Despite promising preclinical evidence of their antioxidant, anti-inflammatory, and anti-apoptotic properties, the clinical use of phytochemicals is limited by issues such as low bioavailability, poor specificity, dose-dependent toxicity, variable pharmacokinetics, and lack of standardisation. Therefore, innovative approaches-such as ligand-targeted delivery systems, nanotechnology-based formulations, and structural modifications of lead compounds-are essential to enhance their pharmacological properties, safety, and therapeutic effectiveness for effective cardioprotection against doxorubicin-induced toxicity.
No takes yet. Share an insight, caveat, or question.
Shyam et al. (2026) studied this question. Phytochemicals show preclinical cardioprotection against doxorubicin toxicity via key pathways but face clinical limitations like low bioavailability and safety concerns.
Synapse has enriched 10 related papers. Consider them for comparative context: